Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome

References

• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017;135:e146–e603.
   PubMed Web of Science ®Google Scholar
• Lucke-Wold BP, DiPasquale K, Logsdon AF, et al. Metabolic syndrome and its profound effect on prevalence of ischemic stroke. Am Med Stud Res J. 2014;1:29–38.
   PubMedGoogle Scholar
• Boden-Albala B, Sacco RL, Lee H-S, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan study. Stroke 2008;39:30–35.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Fu Y, Tian D, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation 2015;132:1104–1112.
   PubMed Web of Science ®Google Scholar
• Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003;108:420–425.
   PubMed Web of Science ®Google Scholar
• Arenillas JF, Moro MA, Dávalos A. The metabolic syndrome and stroke: potential treatment approaches Stroke 2007;38:2196–2203.
   PubMed Web of Science ®Google Scholar
• Darvall KAL, Sam RC, Silverman SH, et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg. 2007;33:223–233.
   PubMed Web of Science ®Google Scholar
• Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417–430.
   PubMed Web of Science ®Google Scholar
• Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.
   PubMedGoogle Scholar
• Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005;46:1978–1985.
   PubMed Web of Science ®Google Scholar
• Nieuwdorp M, Stroes ESG, Meijers JCM, et al. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol. 2005;5:155–159.
   PubMed Web of Science ®Google Scholar
• Kurl S, Laukkanen JA, Niskanen L, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006;37:806–811.
   PubMed Web of Science ®Google Scholar
• Osborn MF, Miller CC, Badr A, et al. Metabolic syndrome associated with ischemic stroke among the Mexican Hispanic population in the El Paso/Border region. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2014;23:1477–1484.
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351–375.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645.
   PubMed Web of Science ®Google Scholar
• Towfighi A, Ovbiagele B. Metabolic syndrome and stroke. Curr Diab Rep. 2008;8:37–41.
   PubMed Web of Science ®Google Scholar
• van Rooy M-J, Pretorius E. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. Thromb Res. 2015;135:434–442.
   PubMed Web of Science ®Google Scholar
• Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005;36:1366–1371.
   PubMed Web of Science ®Google Scholar
• Arenillas JF, Sandoval P, Pérez de la Ossa N, et al. The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men. Stroke 2009;40:344–349.
   PubMed Web of Science ®Google Scholar
• Dorado L, Arenillas JF, López-Cancio E, et al. Metabolic syndrome predicts refractoriness to intravenous thrombolysis in acute ischemic stroke. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2015;24:2605–2612.
   PubMed Web of Science ®Google Scholar
• Palomo I, Alarcón M, Moore-Carrasco R, et al. Hemostasis alterations in metabolic syndrome (review). Int J Mol Med. 2006;18:969–974.
   PubMed Web of Science ®Google Scholar
• Dentali F, Romualdi E, Ageno W. The metabolic syndrome and the risk of thrombosis. Haematologica 2007;92:297–299.
   PubMed Web of Science ®Google Scholar
• Mills JD, Mansfield MW, Grant PJ. Factor XIII-circulating levels and the Val34Leu polymorphism in the healthy male relatives of patients with severe coronary artery disease. Thromb Haemost. 2002;87:409–414.
   PubMed Web of Science ®Google Scholar
• Ninomiya JK, L’Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42–46.
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–689.
   PubMed Web of Science ®Google Scholar
• Arenillas JF, Ispierto L, Millán M, et al. Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke. Neurology 2008;71:190–195.
   PubMed Web of Science ®Google Scholar
• Southerland AM, Johnston KC. Considering hyperglycemia and thrombolysis in the stroke hyperglycemia insulin network effort (shine) trial. Ann NY Acad Sci. 2012;1268:72–78.
   PubMed Web of Science ®Google Scholar
• Cronin CA. Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials. J Emerg Med. 2010;38:99–105.
   PubMed Web of Science ®Google Scholar
• Roy-O'Reilly M, McCullough LD. Sex differences in stroke: the contribution of coagulation. Exp Neurol. 2014;259:16–27.
   PubMed Web of Science ®Google Scholar
• Gravanis I, Tsirka SE. tPA as a therapeutic target in stroke. Expert Opin Ther Targets [Internet]. 2008. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824365/
   PubMed Web of Science ®Google Scholar
• Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost. 2005;93:627–630. Apr
   PubMed Web of Science ®Google Scholar
• IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004;35:904–911.
   PubMed Web of Science ®Google Scholar
• Carter AM, Cymbalista CM, Spector TD, et al. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol. 2007;27:2783–2789.
   PubMed Web of Science ®Google Scholar
• Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost. 2007;5:116–124.
   PubMed Web of Science ®Google Scholar
• Vemmos K, Ntaios G, Spengos K, et al. Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. Stroke 2011;42:30–36.
   PubMed Web of Science ®Google Scholar
• Seet RCS, Zhang Y, Wijdicks EFM, et al. Thrombolysis outcomes among obese and overweight stroke patients: an age- and National Institutes of Health Stroke Scale-matched comparison. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2014;23:1–6.
   PubMed Web of Science ®Google Scholar
• Garavaglia J, Sherman J, Yetzer H, et al. Impact of tissue plasminogen activator dosing on patients weighing more than 100 kg on 3-month outcomes in acute ischemic stroke. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2017;26:1041–1046.
   PubMed Web of Science ®Google Scholar
• Rubiera M, Molina CA. The weight of tissue plasminogen activator dose in overweight patients with strokes. Stroke 2011;42:1503–1504.
   PubMed Web of Science ®Google Scholar
• Diedler J, Ahmed N, Glahn J, et al. Is the maximum dose of 90 mg alteplase sufficient for patients with ischemic stroke weighing >100 kg? Stroke 2011;42:1615–1620.
   PubMed Web of Science ®Google Scholar
• Acheampong P, Ford GA. Pharmacokinetics of alteplase in the treatment of ischaemic c stroke. Expert Opin Drug Metab Toxicol. 2012;8:271–281.
   PubMed Web of Science ®Google Scholar
• Alessi M-C, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost. 2008;99:995–1000.
   PubMed Web of Science ®Google Scholar
• Menon BK, Smith EE, Coutts SB, et al. Leptomeningeal collaterals are associated with modifiable metabolic risk factors. Ann Neurol. 2013;74:241–248.
   PubMed Web of Science ®Google Scholar
• Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost. 2004;91:S1146–S1151.
   PubMed Web of Science ®Google Scholar